Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S.Roy Kimura, “Alivexis”), a preclinical stage technology-driven drug discovery company, will present ModBind™, our drug discovery platform at MACNICA, Inc. booth at the 5^th AI EXPO Tokyo held at Makuhari Messe, Tokyo on November 20^th-22^nd, 2024.

The AI EXPO Tokyo is the largest trade show about AI in Japan which is expected to attract tens of thousands of people to join.  MACNICA, Inc., as an official distributor of NVIDIA products and services, will present accelerated computing technology and software developed by NVIDIA with a wide range of AI solutions which consolidates many cutting-edge methodologies developed by multiple global partner companies.

ModBind™ is our proprietary platform technology which enables unprecedently fast, highly accurate, and absolute prediction of binding affinity of small molecules against their target proteins.  Alivexis has already delivered multiple clinical candidates using ModBind™, and one of our candidate compounds was recently successfully out-licensed to biopharma. Considering the method’s scalability and accuracy, Alivexis is further enhancing ModBind™ to enable large-scale production of synthetic data to train cutting-edge drug discovery AI models.  At the AI EXPO Tokyo, Alivexis will present its collaboration involving the synergistic combination of ModBind™ with NVIDIA BioNeMo™, a powerful AI platform enabling the discovery, characterization, and optimization of various types of biomolecules relevant in drug discovery.

Alivexis’ presentation schedule:
Date: 10:00-16:00, November 20^th-22^nd, 2024 JST (actual time of presentations is TBD)
Venue: MACNICA booth at 5th AI EXPO Tokyo (held at Makuhari Messe)

Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo(PDF)